Navigation Links
AssureRx Expands GeneSightRx® Pharmacogenetic Profile with Sixth Gene to Enhance Guidance of Psychiatric Drug Prescribing
Date:2/14/2011

reatment of patients with neuropsychiatric and other disorders."

John A. Bellano, senior vice president of sales & commercial programs at AssureRx Health said, "Variations of the CYP2C9 gene affect several commonly used psychiatric medications. Its inclusion in GeneSightRx allows us to further differentiate the AssureRx technology from routine genotyping tests. Enhancing GeneSightRx with the CYP2C9 gene now provides physicians with even more information about their patients' unique genetic fingerprint, allowing them to make more informed medication choices for each individual patient. Our goal is to provide treatment-oriented support that helps reduce the risk of side effects and delays in achieving response."

About GeneSightRxGeneSightRx is a laboratory developed genetic test that uses cutting edge technology to measure and analyze clinically important genetic variants in psychiatric medicine. The results of the report can help a doctor understand the way a patient's unique genetic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenetics, the study of the genetic factors that influence an individual's response to drug treatments, the FDA approved manufacturer's drug label, and scientifically valid published reports and/or proven pharmacology. Quick turnaround time, combined with a customized report of the patient's genetic makeup, clinical experience, and other factors can help a physician make personalized drug treatment choices for each individual patient. To learn more about pharmacogenetics and GeneSightRx, please click here. Be sure to watch the educational video.

About AssureRx HealthCincinnati-based AssureRx Health, Inc. is a personalized medicine company that specializes in pharmacogenetics and is dedicated to helping physicians determine the right drug at the right dose for individual patients suffering from psychiatric disorders.
'/>"/>

SOURCE AssureRx Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AssureRx Appoints Senior Executives in Key Roles to Drive Company Growth
2. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
3. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
4. Cellectar Expands Clinical Management Team
5. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
6. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
7. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
8. PAREXEL Expands Global Clinical Pharmacology Capabilities
9. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
10. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
11. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... ALBANY, N.Y. , March 5, 2015  AMRI ... Michael Pettersson , fills the newly created position of ... Christopher Conway , Senior Vice President of Global ... Mr. Pettersson will lead the international sales team in ... market share in targeted market segments. Mr. Pettersson will ...
(Date:3/5/2015)... - Cross reference: Picture is ... - Hitachi Medical Systems Europe è ... OASIS* all,ECR 2015. Si tratta di un sistema ... T che migliora la capacità diagnostica dei sistemi già ... del paziente. Le nuove funzionalità di OASIS permettono una ...
(Date:3/5/2015)... PRINCETON, N.J. , March 5, 2015 ... late stage biopharmaceutical company committed to developing products that ... oncology and biodefense, announced today that its President and ... will give a corporate presentation at the 27 th ... California , on Tuesday, March 10, 2015 at ...
Breaking Medicine Technology:AMRI Hires VP of International Sales 2Hitachi Medical Systems Europe lancia la nuova generazione di OASIS*: Il sistema di RM aperta ad alto campo da 1.2 T. Ancora più valore al paziente 2Hitachi Medical Systems Europe lancia la nuova generazione di OASIS*: Il sistema di RM aperta ad alto campo da 1.2 T. Ancora più valore al paziente 3Hitachi Medical Systems Europe lancia la nuova generazione di OASIS*: Il sistema di RM aperta ad alto campo da 1.2 T. Ancora più valore al paziente 4Soligenix to Present at the 27th Annual ROTH Conference 2Soligenix to Present at the 27th Annual ROTH Conference 3
... median survival vs. ... parallel external controls -, IRVINE, Calif., Nov. 2 ... from the Phase 2 study of,its investigational agent IDM-2101 which showed ... responses,and showed a positive survival trend in patients with non-small cell ...
... In a move to improve,significantly the safety ... emergency medical information service, has joined,the Alzheimer,s Association ... offer MedicAlert(R) + Safe Return(R). Currently, there are ... almost 10 million,people caring for someone with Alzheimer,s ...
Cached Medicine Technology:IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients 2IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients 3IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients 4MedicAlert Foundation Joins The Alzheimer's Association to Offer MedicAlert(R) + Alzheimer's Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies 2MedicAlert Foundation Joins The Alzheimer's Association to Offer MedicAlert(R) + Alzheimer's Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies 3
(Date:3/5/2015)... CA (PRWEB) March 05, 2015 A Bakersfield, ... a seven-week trial awarding the plaintiff Coleen M. ... as a result of a TVT-Abbrevo pelvic mesh sling device, ... , Tom Cartmell , a partner at Wagstaff ... trial team for the plaintiff, along with Rich Freese and ...
(Date:3/5/2015)... March 05, 2015 Risperdal lawsuits ... a Pennsylvania mass tort litigation currently underway in ... jury has begun hearing testimony in the proceeding’s ... antipsychotic medication can cause gynecomastia, or male breast ... question was filed on behalf of a plaintiff ...
(Date:3/5/2015)... Central Nebraska Imaging (CNI) is pleased to ... new logo and optimized website. , CNI’s ... to expert diagnostic imaging, centered on patient care. The ... be a resource for Nebraska patients and a tool ... and referral functionality, video content and resources to understand ...
(Date:3/5/2015)... HomeCEUConnection.com is proud to support Nutrition ... their nutrition CEUs. To raise awareness on ... is offering 10% off selected nutrition CEU ... . , High Quality Continuing Education for ... continuing education courses for Physical Therapists, Physical ...
(Date:3/5/2015)... Angeles, CA (PRWEB) March 05, 2015 ... article titled “Butt Augmentation, Labiaplasty on the Rise, Plastic ... reported by the American Society for Aesthetic Plastic ... Surgeons . Both groups reported a year-over-year doubling of ... of the physicians quoted in the article, this increase ...
Breaking Medicine News(10 mins):Health News:Client Wins $5.7 Million in TVT-Abbrevo Verdict against Johnson & Johnson in California State Court 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 3Health News:Central Nebraska Imaging Center Gets Rebranding 2Health News:HomeCEUConnection.com Offers Nutrition CEUs this March to Celebrate Nutrition Month 2Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2
... FORT WORTH, Texas, June 15 Female caregivers of African American ... papillomavirus (HPV), according to a new study by the Center for ... Worth, Texas. , , The HPV Vaccine Acceptability Study discovered ... , Most ...
... thread, researcher says , MONDAY, June 15 (HealthDay News) ... major cardiovascular disease and death, a new study finds. ... Administration medical facility study to compare 3,236 people suffering ... a 78 percent higher incidence of heart disease, a ...
... , WASHINGTON, June 15 Just as Congress begins to ... since Medicare became law in 1965, Hudson Institute will debate ... 17th. , , Health costs will define the long-term ... care costs will be the topic of the Hudson panel. ...
... Va., June 15 Escalating funding issues challenge social ... across the country indicate that decreasing funds impact both ... state governments face new budget years a stark reality ... that provide minimal, but essential, services to the country,s ...
... New Pharmacy Benefit Evaluator Analyzes Health Plan Pharmacy Benefit ... Care Sales Strategy Development , , NASHVILLE, Tenn., ... care market intelligence, has enhanced its Pharmacy ... health plan pharmacy benefit structure and spending and the ...
... special interest," says campaign finance watchdog group , ... has spent $204.4 million to influence Congress and Administrations over ... contributions over the last two decades, according to a Public ... Responsive Politics website. , , "When President Obama addresses ...
Cached Medicine News:Health News:HPV Vaccine Acceptability Study Announces Results 2Health News:HPV Vaccine Acceptability Study Announces Results 3Health News:Psoriasis Raises Risk of Heart Attack, Stroke, Death 2Health News:Hudson Institute Debates the Long-Term Fiscal Impact of Health Care Reform 2Health News:Government Must Not Balance Budget on the Backs of the Poor 2Health News:Government Must Not Balance Budget on the Backs of the Poor 3Health News:HealthLeaders-InterStudy Launches Pharmacy Benefit Evaluator 2Health News:Backgrounder: As Obama Makes Pitch to AMA, the Group Tries to Call in its Political Investment in Congress 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: